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Abstract
Background: Activation of the extrinsic apoptosis pathway by tumour necrosis factor related apoptosis inducing 
ligand (TRAIL) is a novel therapeutic strategy for treating cancer that is currently under clinical evaluation. Identification 
of molecular biomarkers of resistance is likely to play an important role in predicting clinical anti tumour activity. The 
involvement of the mitochondrial type 1 voltage dependent anion channel (VDAC1) in regulating apoptosis has been 
highly debated. To date, a functional role in regulating the extrinsic apoptosis pathway has not been formally excluded.
Methods: We carried out stable and transient RNAi knockdowns of VDAC1 in non-small cell lung cancer cells, and 
stimulated the extrinsic apoptotic pathway principally by incubating cells with the death ligand TRAIL. We used in-vitro 
apoptotic and cell viability assays, as well as western blot for markers of apoptosis, to demonstrate that TRAIL-induced 
toxicity is VDAC1 dependant. Confocal microscopy and mitochondrial fractionation were used to determine the 
importance of mitochondria for caspase-8 activation.
Results: Here we show that either stable or transient knockdown of VDAC1 is sufficient to antagonize TRAIL mediated 
apoptosis in non-small cell lung cancer (NSCLC) cells. Specifically, VDAC1 is required for processing of procaspase-8 to 
its fully active p18 form at the mitochondria. Loss of VDAC1 does not alter mitochondrial sensitivity to exogenous 
caspase-8-cleaved BID induced mitochondrial depolarization, even though VDAC1 expression is essential for TRAIL 
dependent activation of the intrinsic apoptosis pathway. Furthermore, expression of exogenous VDAC1 restores the 
apoptotic response to TRAIL in cells in which endogenous VDAC1 has been selectively silenced.
Conclusions: Expression of VDAC1 is required for full processing and activation of caspase-8 and supports a role for 
mitochondria in regulating apoptosis signaling via the death receptor pathway.
Background
The voltage dependent anion channel 1 (VDAC1) is a
conserved beta barreled pore forming protein integral to
the outer mitochondrial membrane where it regulates
ATP/ADP exchange and respiratory control [1]. The
functional role of the VDAC proteins VDAC1, 2, and 3 in
the regulation of apoptosis remains controversial. Differ-
ent VDAC proteins exhibit distinct apoptosis regulating
functions as evidenced by the antagonism of BAK-
induced apoptosis by VDAC2 [2]. A pro-apoptotic role
for VDAC1 has been implicated in some cell death mod-
els. For example, knockdown of VDAC1 has been
reported to abrogate BAX activation and apoptosis fol-
lowing cisplatin treatment in NSCLC cells [3]. VDAC1
has been shown to be required for endostatin-induced
endothelial cell apoptosis [4]. Knockout of all three
VDAC isoforms does not indicate a direct role in regulat-
ing calcium or BID induced mitochondrial apoptosis [5].
However, hexokinase II binds VDAC1 and this interac-
tion has been implicated in regulating cell survival down-
stream of AKT [6], and blocking ion transport through
VDAC1 following toxic insult has been shown to reduce
subsequent apoptosis [7].
The potential involvement of VDAC1 in regulating
death receptor mediated apoptosis has not been deter-
mined. The extrinsic death pathway involves binding of
ligands such as TRAIL [8] or FAS [9] to receptors of the
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Tumour Necrosis Factor Receptor family. This results in
recruitment and activation of initiator caspase-8 at the
death-inducing signaling complex (DISC), resulting in
cleavage of the 53/55 kDa procaspase to catalytically
active p43 and p18 forms [10]. Cleaved caspase-8 then
directly activates the executioner caspases 3 and 7 [11],
and the mitochondrial apoptosis pathway through cleav-
age of the 23 kDa BID protein to its truncated form tBID,
promoting oligomerisation of BAX and BAK [12,13].
Mitochondrial cardiolipin has been proposed to regulate
translocation and activation of caspase-8, implicating this
organelle in extrinsic death pathway regulation [14,15],
and a number of studies have shown that procaspase-8
and p18-caspase-8 localise to the mitochondria [16-18].
Non-small cell lung cancer (NSCLC) cells express rela-
tively high levels of procaspase-8 and are sensitive to
induction of apoptosis by TRAIL compared with normal
cells both in vitro and in vivo [19,20]. Accordingly, there is
interest in the potential clinical application of TRAIL,
and TRAIL receptor agonists in NSCLC and other
tumour types [20,21]. In this study we show that VDAC1
is necessary for full caspase-8 activation and apoptosis
following activation of death receptors by TRAIL, FAS or
FLIP siRNA knockdown in NSCLC cells, implicating a
novel functional role for mitochondria in regulating
death ligand induced apoptosis.
Results
Knockdown of VDAC1 inhibits TRAIL induced apoptosis
To examine the potential role of VDAC1 in regulating
extrinsic pathway death signaling in NSCLC cells, we cre-
ated H460 clones, stably expressing shRNA targeted to
VDAC1. Two stable clones with different VDAC1 target-
ing sequences were generated and compared with non-
targeting shRNA (sh-NT). VDAC1 protein expression in
clones V1-1B and V1-2A was reduced to almost unde-
tectable levels by Western blot (Figure 1A). Following
exposure to IC50 concentration of TRAIL ligand, sh-NT
control cells reduced their viability; however this did not
occur in sh-VDAC1 cells (Figure 1B). Induction of apop-
tosis evidenced by sub-G0/G1 fraction was inhibited by
VDAC1 silencing (Figure 1C), as was TRAIL-induced
activation of caspase-3 (Figure 1D). Cleavage of poly-
ADP ribose polymerase (PARP) to its truncated form
(ΔPARP) was observed in TRAIL treated sh-NT clones,
but not in sh-VDAC1 clones (Figure 1E). As confirmation
of these findings, transient knockdown of VDAC1 using a
different siRNA sequence (Figure 1F) also prevented cas-
pase-3 activation following TRAIL (Figure 1G). These
data indicate that knockdown of VDAC1 inhibits TRAIL-
induced apoptosis.
VDAC1 is required for TRAIL induced mitochondrial 
formation of Caspase-8-p18
Caspase-8 localises to mitochondria in various cell lines,
where it can undergo further processing and activation
[14-18]. Using confocal microscopy, we examined locali-
sation of caspase-8 in H460 cells. Caspase-8 partially
colocalised with the mitochondrial marker COX-4 (Fig-
Figure 1 VDAC1 silencing blocks TRAIL induced apoptosis. (A) 
Western blot showing H460 clones with stable knockdown of VDAC1 
by different shRNA sequences (V1-1B and V1-2A), and control cells ex-
pressing non-targeting shRNA (NT). (B) ATPase viability assay showing 
reduction in viability 24 h following 10 ng/ml TRAIL treatment, which 
is significantly attenuated in VDAC1 knockdown clones compared to 
NT control cells (*p < 0.0001 v sh-NT). (C) Flow cytometry of PI-stained 
H460 clones following TRAIL treatment. Apoptotic cells are indicated 
by increase in sub-G0/G1 population (*p < 0.05). (D) Luminescent 
DEVD-ase assay measures caspase-3-like activity in sh-NT and sh-
VDAC1 cells 24 h after TRAIL treatment (10 ng/ml), shown relative to 
time-match control for each cell line. Increase in caspase-3 activity in 
NT control is significantly attenuated in sh-VDAC1 cells (*p < 0.0005 v 
sh-NT). (E) Western blot for PARP in sh-NT and sh-VDAC1 cells follow-
ing TRAIL treatment. PARP cleavage occurs in sh-NT control cells but 
not sh-VDAC1-1B or sh-VDAC1-2A cells. (F) Western blot of H460 cells 
transiently transfected with siRNA to VDAC1 (V1) or Non-Targeting siR-
NA (NT). (G) Transient siRNA knockdown of VDAC1 was carried out and 
cells were treated with TRAIL. DEVD-ase assay showing significant at-
tenuation of caspase-3-like activity following VDAC1 knockdown.Chacko et al. BMC Cancer 2010, 10:380
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ure 2A). Colocalisation was most evident in the perinu-
clear region, although cytosolic foci of caspase-8 were
visible outwith the mitochondrial COX-4 stained area.
We therefore examined whether VDAC1 expression
affects caspase-8 processing in the mitochondrial com-
partment. H460 cells were transfected with VDAC1
siRNA or non-targeting (NT) siRNA, incubated with
TRAIL for 24 h, and mitochondrial and cytosolic frac-
tions extracted. Activation of caspase-8 involves process-
ing of the 53 kDa pro-caspase zymogen, and intermediate
forms, to the catalytically active p18 form. Following
TRAIL treatment, activation of caspase-8-p18 protein
was observed in the mitochondrial fraction from NT
control cells, but this was abolished by VDAC1 silencing
(Figure 2B). The active caspase-8-p18 protein was con-
centrated in the mitochondrial fraction. Cleavage of cas-
pase-8 to p18 was also significantly reduced following
TRAIL in the sh-VDAC1 knockdown cells, whereas cas-
pase-8 p18 was strongly detected in the mitochondrial
fraction of sh-NT control cells (Figure 2C).
To confirm whether the VDAC1 requirement for cas-
pase-8 activation could be generalised to other cells,
VDAC1 was silenced in the MOR NSCLC cell line. Fol-
lowing 10 ng/ml TRAIL, strong accumulation of caspase-
8-p18 was observed in NT siRNA treated cells, but this
was abolished by knockdown of VDAC1 (Figure 2D). A
similar effect was observed in SKMES (Figure 2E),
although only p43-caspase-8 was readily detectable in
these cells. These results indicate that TRAIL-induced
caspase-8 cleavage and apoptosis are VDAC1-dependent.
To exclude alterations in the expression of DISC pro-
teins due to clonal selection in sh-VDAC1 cells, the integ-
rity of key components of the DISC was examined.
Expression levels of TRAIL receptor DR5, caspase-8
antagonist c-FLIP, and caspase-8 recruiting protein
FADD were all unchanged in sh-VDAC1 clones as com-
pared with sh-NT cells (Figure 3A). No differences in cell
surface expression of TRAIL receptor DR5 were detected
in the sh-VDAC1 cells compared with sh-NT cells; DR4
was barely detectable in all cells (Figure 3B).
VDAC1 regulates TRAIL induced BID cleavage and 
mitochondrial apoptosis
Caspase-8 activates the mitochondrial (intrinsic) apopto-
sis pathway by cleaving BID to its truncated, active iso-
form, tBID, which then directly activates BAX and BAK
[12,13]. Inhibition of caspase-8 should therefore prevent
mitochondrial BAX/BAK activation by TRAIL. To test
this hypothesis TRAIL-induced BAX oligomerization
was measured by cross-linking of mitochondria with
BMH. This was not observed in the sh-VDAC1 clones
compared with sh-NT clones in which dimeric and tri-
meric oligomers of BAX were clearly formed (Figure 4A).
Processing of BID was markedly reduced in sh-VDAC1
cells following TRAIL treatment compared to sh-NT
clones (Figure 4B). Mitochondrial outer membrane per-
meabilization evidenced by release of cytochrome C was
observed following TRAIL in sh-NT cells, but not in sh-
VDAC1 cells (Figure 4C). The lack of intrinsic pathway
Figure 2 VDAC1 silencing blocks cleavage of caspase-8 to its p18 
subunit. (A) Confocal microscopy image showing colocalisation of 
Caspase-8 (green) with the mitochondrial marker protein COX-4 (red) 
in H460 cells. Colocalisation is indicated by yellow staining in merged 
image. (B) Caspase-8 western blot of mitochondrial and cytosolic frac-
tions of cells transiently transfected with NT siRNA or VDAC1 siRNA. 
Catalytically active caspase-8-p18 appears in NT-siRNA control, but not 
VDAC1-siRNA cells, following TRAIL. Caspase-8-p18 is predominantly in 
mitochondrial fraction, but excluded from cyotsolic fraction. COX4 blot 
is shown as mitochondrial marker; α-tubulin is shown as cytosolic 
marker. (C) Caspase-8 western blot on mitochondrial fraction from 
H460 shRNA clones treated with 10 ng/ml TRAIL for 24 h. Appearance 
of 18 kDa form of caspase-8 is strong in mitochondrial fraction of sh-NT 
control cells but is abolished in sh-VDAC1-1B and sh-VDAC1-2A cell 
lines. COX4 is shown as mitochondrial loading control. (D) Caspase-8 
western blot of cell lysates from MOR cell line transfected with NT siR-
NA or VDAC1 siRNA. Caspase-8-p18 appears in NT-siRNA control, but 
not VDAC1-siRNA cells, following 10 ng/ml TRAIL treatment. (E) Cas-
pase-8 western blot of cell lysates from SKMES cell line transfected with 
NT siRNA or VDAC1 siRNA. Increase in caspase-8 activation to p43 iso-
form is detected in NT-siRNA cells following 50 ng/ml TRAIL, but not in 
VDAC1-siRNA cells. Caspase-8 p18 was not detectable in SKMES cell 
line at reasonable concentrations of TRAIL.Chacko et al. BMC Cancer 2010, 10:380
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activation following TRAIL in VDAC1 silenced cells
could be due to impairment of BAX/BAK activation, if
they are regulated by VDAC1. To test this hypothesis,
mitochondria isolated from sh-NT control cells and sh-
VDAC1 knockdown cells were incubated with recombi-
nant caspase-8-cleaved BID (tBID). Mitochondrial depo-
larisation induced by tBID was not inhibited by VDAC1
silencing (Figure 4D). Taken together, VDAC1 is required
for TRAIL-induced caspase-8 processing of BID leading
to inhibition of TRAIL-induced BAX activation and cyto-
chrome C release, but does not affect the mitochondrial
apoptotic response downstream of tBID.
VDAC1 is required for caspase-8 activation induced by FAS 
ligand and FLIP silencing
To determine if VDAC1 could regulate caspase-8 activa-
tion induced by extrinsic pathway agonists other than
TRAIL, cells were treated with FAS ligand (CH11), re-
plated, and clonogenicity examined after 7 days. FAS
ligand treatment caused particularly significant attenua-
tion of cell growth (Figure 5A). CH11 also caused strong
activation of caspase-8 and appearance of the p18 form in
sh-NT cells, but this was again absent in sh-VDAC1 cells
following CH11 treatment (Figure 5B).
Silencing of c-FLIP has been shown to induce caspase-8
activation in a number of NSCLC cell lines, including
H460 [19]. Accordingly, the role of VDAC1 in regulating
apoptosis induced by cFLIP knockdown was also exam-
ined. FLIP silencing by siRNA induced accumulation of
caspase-8-p18 in sh-NT control cells, but this was not
observed in sh-VDAC1 cells (Figure. 5C).
Figure 3 DISC components are unchanged in VDAC1 knockdown 
cells. (A) Western blots showing expression of TRAIL receptor DR5, c-
FLIP, and FADD, which are of comparable levels in sh-NT control and 
sh-VDAC1 cells, both before and after TRAIL treatment. (B) Flow cy-
tometry showing cell surface expression of TRAIL receptors DR4 and 
DR5 in sh-NT and sh-VDAC1 cell lines. All cells show high levels of DR5 
expression and relatively low levels of DR4.
Figure 4 VDAC1 silencing blocks TRAIL induced mitochondrial 
apoptosis. (A) Western blot of BAX in BMH-crosslinked mitochondrial 
fraction from TRAIL-treated or time-matched cells. Dimers and trimers 
of BAX indicating BAX activation appear in NT cells following TRAIL but 
this is reduced in VDAC1 knockdown cells. (B) Western blot of BID in 
sh-NT and sh-VDAC1 cells. Full length p23-BID is activated by caspase-
8 mediated cleavage in mitochondria following TRAIL treatment in sh-
NT control cells but is not processed in the VDAC1 knockdown cells. 
We were unable to detect the 16 kDa tBID fragment by western blot. 
COX4 is shown as loading control. (C) Western blot of cytochrome-C in 
mitochondrial fraction of sh-NT and sh-VDAC1-2A cells. Cyt-C is lost 
from sh-NT control mitochondria following TRAIL, indicating mito-
chondrial outer membrane permeabilization (MOMP). MOMP is not 
observed in VDAC1 knockdown cells. (D) Mitochondria were extracted 
from cells shown and were resuspended in respiration buffer and 
stained with JC-1 dye (see methods) to measure mitochondrial polar-
ization status. 25 μg of mitochondria were aliquoted per well of 96-well 
plate (n = 5) and incubated with recombinant caspase-8-cleaved BID 
(tBID) at concentrations shown for 45 minutes. 1% Triton-X treatment 
was used as positive control for full depolarization. Ratio of green (530 
nm) to red (580 nm) fluorescence of JC-1 increases as mitochondria 
depolarize.Chacko et al. BMC Cancer 2010, 10:380
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Exogenous VDAC1-Myc restores TRAIL induced apoptosis 
in cells with silenced endogenous VDAC1
To determine whether re-expression of exogenous
VDAC1 could restore sensitivity to TRAIL in cells in
which endogenous VDAC1 had been selectively silenced
by siRNA targeting the 3' untranslated region (3'UTR) of
VDAC1, H460 clones stably expressing the full length
coding region of VDAC1 fused to Myc-tag were gener-
ated. Clones 5A and 5B exhibited moderate increases in
overall expression of VDAC1 compared to empty vector
control cells (Figure 5E). Cells stably expressing empty
vector (EV) or VDAC1-myc were treated with NT siRNA
or a VDAC1 3'UTR siRNA. Following treatment with
TRAIL, VDAC1-myc transfected cells exhibited
increased activation of caspase-3 compared to control
cells (Figure 5D). Control cells also showed a lack of
TRAIL induced caspase-8 processing to p18 (Figure 5F).
In VDAC1-myc overexpressing cells, however, PARP pro-
cessing occurred to a greater degree compared to control
(Figure 5G), and was unaffected by silencing of endoge-
nous VDAC1.
Discussion
The role of VDAC1 in regulating apoptosis has been the
subject of considerable debate. Knockout of all three iso-
forms of VDAC was shown to have no effect on mito-
chondrial apoptosis in mouse embryonic fibrosis [5],
whereas conflicting data has indicated that the N-termi-
nal of VDAC1 is essential for release of cytochrome C fol-
lowing various apoptotic stimuli [22]. VDAC2 has been
shown to inhibit BAK activation in a similar manner to a
BCL2 family protein [2]; however recent data suggests
that VDAC2 also has a proapoptotic role associated with
regulation of BAK and BAX [23,24]. VDAC1 promotes
aerobic glycolysis in cell lines through its interaction with
hexokinase at the outer mitochondrial membrane [25,26].
Other studies have shown that hexokinase binds to mito-
chondria via the N-term of VDAC1 and that this is asso-
ciated with resistance to mitochondrial apoptosis [27,28].
These reported interactions between VDAC1 and
hexokinase imply a pro-survival rather than pro-apop-
totic role for VDAC1 activity in cancerous cells.
VDAC1 interacts directly with, and may be functionally
regulated by the anti-apoptotic BCL-2 family protein
BCL-XL [1,29-32] or the proapoptotic BH3-only proteins
BAD [33] and BID [34]. The mitochondrion has been
previously implicated in BAX/BAK independent regula-
tion of extrinsic death pathway signaling. BCL-XL can
inhibit cleavage of caspase-8 at the mitochondrial surface
following treatment with FAS ligand [15]. Confocal
microscopy showed that caspase-8 partially colocalised
with a mitochondrial marker in H460 cells, and western
blot indicated that pro-caspase-8 was divided between
mitochondrial and cytosolic fractions. This is consistent
with previous studies which have demonstrated pro-cas-
pase-8 and p18-caspase-8 localization to the mitochon-
dria [16-18]. We observed that TRAIL induced cleavage
of caspase-8 to the active p18 protein, which was
detected predominantly in the mitochondrial compart-
Figure 5 VDAC1 is required for FAS ligand-induced and FLIP si-
lencing-induced activation of caspase-8. (A) Clonogenic assay 
shows impairment of cell regrowth in sh-NT and sh-VDAC1 cells fol-
lowing exposure to TRAIL or CH11. Clonogenicity is significantly re-
duced in sh-VDAC1 cells compared to sh-NT cells for both death 
ligands. (B) Cells were treated with 150 ng/ml FAS ligand CH11. West-
ern blot shows that caspase-8-p18 is generated in sh-NT cells following 
treatment with CH11, but this is significantly reduced in sh-VDAC1 
cells. (C) sh-NT or sh-VDAC1 cells were transfected with c-FLIP, or 
scrambled control siRNA. Caspase-8-p18 was detectable 24 h post FLIP 
siRNA treatment in sh-NT cells, but not sh-VDAC1 cells. H460 cells were 
generated that stably expressed the coding region only of VDAC1 
fused to myc epitope tag (pVDAC1-5A or pVDAC1-5B), or empty vector 
(EV). (D) DEVDase assay showing increased caspase-3 activity in 
pVDAC1 cells following 10 ng/ml TRAIL treatment, which is unaffected 
by V1-3' siRNA, whereas control cells show reduced caspase-3 activity 
in comparison, which is significantly attenuated by V1-3'siRNA. (E) 
Western blot shows expression of Myc tag and a moderate increase in 
overall VDAC1 in pVDAC1-5A and pVDAC1-5B. (F) siRNA targeting 
3'UTR of VDAC1 [V1(3')] causes moderate VDAC1 knockdown in EV 
cells, but not in pVDAC1 cells. TRAIL treatment shows that V1(3') siRNA 
reduces processing to Casp-8 (p18) in EV cells. (G) Myc-tagged VDAC1 
expressing cells exhibit increased sensitivity to TRAIL as shown by in-
creased processing of PARP.Chacko et al. BMC Cancer 2010, 10:380
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ment, and that this was dependent upon expression of
VDAC1 in various NSCLC cell lines.
This study is the first to implicate VDAC1 in the regula-
tion of extrinsic pathway mediated apoptosis. Using both
stable and transient knockdown of VDAC1 we have
shown that death receptor dependent apoptosis relies on
the expression of this outer mitochondrial membrane
protein for efficient processing of caspase-8. VDAC1 did
not appear to directly affect BAX/BAK dependent activa-
tion by tBID, in agreement with a recent finding that
mitochondria from VDAC1(-/-) MEFs remained sensitive
to tBID [23]. Accordingly, the mitochondrial VDAC1
directly regulates the extrinsic apoptotic pathway via cas-
pase-8 and indirectly regulates the mitochondrial death
pathway via BID processing, implicating a previously
unknown proapoptotic, and physiological function for
VDAC1.
Although our findings suggest that downstream of
death ligand binding, VDAC1 acts as a facilitator of cas-
pase-8 processing, it is not known whether VDAC1
requires cooperation with additional proteins in the outer
mitochondrial membrane or is sufficient to activate cas-
pase-8. Recent evidence has shown that caspase-8 locali-
sation occurs at contact sites where cardiolipin, a
predominantly inner mitochondrial membrane phospho-
lipid, is exposed at the mitochondrial surface; however,
the binding interactions of caspase-8 at the mitochondria
remain undefined [14]. VDAC1 is also present at contact
sites on the outer mitochondrial surface raising the possi-
bility that loss of VDAC1 could in some way alter contact
site architecture and the cardiolipin platform for caspase-
8 docking. One argument against this from our own and
previous data however, is that significant levels of procas-
pase-8 are present in the mitochondrial outer membrane
in the absence of TRAIL. It is therefore unclear by what
molecular mechanism VDAC1 may regulate caspase-8
cleavage. Caspase-8 processing to p18 may occur at the
mitochondria in a VDAC1-dependent manner leading to
a signal amplification loop following binding of death
ligand and DISC assembly. Such an amplification loop
could be reliant on active caspase-3, which accumulates
in the mitochondria following etoposide-induced cell
death [18].
The structural requirements for VDAC1 regulation in
regulating caspase-8 activation are unknown. The E3
ligase Cullin-3 polyubiquitinates caspase-8 prior to its
cleavage at the DISC following death receptor stimulation
[35], and VDAC1 could play a regulatory role in this pro-
cess. We cannot rule out the possibility that VDAC1 may
promote caspase-8 cleavage by associating with DISC
components at the plasma membrane; redox activity of
VDAC1 at the plasma membrane has been shown to reg-
ulate apoptosis [7,36]. Further studies are required to
delineate the domains and protein interactions which are
essential for VDAC1 to regulate caspase-8 activation;
such studies are ongoing and will investigate whether this
function is specific to VDAC1 alone, or shared by other
VDAC isoforms due to local homology in critical
domains.
Conclusions
In summary, we have shown that VDAC1 is required for
activation of caspase-8 following stimulation of the
extrinsic apoptosis pathway in a panel of NSCLC cells.
TRAIL is currently being investigated in the clinical set-
ting as a potential anticancer therapy; trials are ongoing
in NSCLC [20,21]. Our findings suggest that expression
levels of VDAC1 could be a factor predictive for tumour
sensitivity to therapeutic TRAIL receptor agonists in a
subset of cancers.
Methods
Cell Culture and Generation of Stable shRNA Expressing 
Clones
ATCC-NCI-H460 Non-Small Cell Lung Cancer Cells,
and MOR cells, were grown in RPMI 1640 medium
(PAA) with 10% fetal calf serum and penicillin/strepto-
mycin at 37°C with 5% CO2. SKMES cells were grown in
EMEM media. Plasmids encoding shRNA sequences to
VDAC1 and Non-Targeting (NT) shRNA (SA Biosci-
ences) were transfected into H460 NSCLC cells using
FuGene6 reagent (Roche) according to manufacturer's
instructions. Plasmids bore G418 antibiotic resistance
selection marker and transfected cells in 12-well plate
were incubated with 0.4 mg/ml G418 until discrete colo-
nies visible to the naked eye could be selected for trans-
f e r r a l  t o  a  f r e s h  p l a t e .  T h r ee  r o u n d s  o f  s e l e c t i o n  w e r e
preformed and clones which grew steadily in the pres-
ence of antibiotic were tested for knockdown of protein
of interest by western blot. Cells were cultured continu-
ously in the presence of appropriate antibiotics, but anti-
biotics were removed when plating for drug treatment.
SiRNA knockdown
Cells were transfected with 50 nM of VDAC1 on-target
siRNA smartpool (Dharmacon), VDAC1_11 siRNA
sequence (Qiagen) or Non-Targeting siRNA using Dhar-
mafect-1 reagent. Following transfection, transfection
media was replaced with RPMI 1640 media, cells incu-
bated for 24 h, trypsinized and seeded for experiments
described in text (5000 cells/well for 96-well plate). End-
point was taken 24 h post TRAIL treatment and 48 h post
siRNA transfection.
Mitochondrial Isolation and Depolarisation Experiments
Cells typically 90% confluent were detached with a cell
scraper into culture media, pelleted by centrifugation to
include non-adherent cells, if any, and washed threeChacko et al. BMC Cancer 2010, 10:380
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times in Mitochondrial Isolation Buffer (200 mM Manni-
tol, 70 mM Sucrose, 1 mM EGTA, 10 mM HEPES, 0.5
mg/ml BSA, pH7.4). Mitochondria were then isolated by
Dounce homogenization followed by centrifugation at
800 g for 10 minutes to remove debris and heavy mem-
branes, then centrifugation at 10,000 g for 10 minutes to
separate mitochondria from cytosolic fraction. For mea-
surement of mitochondrial polarization, approximately 1
mg mitochondria were resuspended in 800 μl of respira-
tion buffer (125 mM KCl, 5 mM HEPES, 1 mM EGTA, 1
mM KHP04, 2.5 mM MgCl2, 0.4% BSA, pH 7.4) with 5
μM Rotenone. Mitochondria were then loaded with JC-1
(10 nM) (Invitrogen), incubated for 5 minutes at 37°C,
and washed and centrifuged 3 times in 800 μl MRB. 50 μl
of mitochondria solution was applied to each well of a 96
well plate, with final volume made to 100 μl by applying
treatment as described in text. Mitochondria were incu-
bated at 37°C and JC-1 fluorescence measured at 530 nm
(green) and 580 nm (red) with excitation at 480 nm.
Results were summarized as mean ± standard deviation.
Western Blotting
25 μg of cell lysate or mitochondrial fractions were loaded
into a 12% SDS-PAGE gel. Proteins were separated by
electrophoresis and transferred to PVDF membrane for
b l oc k i n g  a n d  i n c u b a t i o n  i n  5 %  m i l k  w i t h  p r i m a ry  a n d
HRP-conjugated secondary antibodies. Images were
developed with ECL-plus (GE healthcare). Alternatively,
fluorescently tagged secondary antibodies were used for
analysis of Western blot on Licor Odyssey Imaging sys-
tem. Primary antibodies used were; anti-VDAC1 (Abcam
ab14734), anti-PARP (E-Bioscience 14-6666-92), anti-
Caspase-8 (Alexis 804-242) anti-BAX (Cell Signaling
#2774), anti-COX4 (Cell Signaling #4850), anti-BID (Cell
Signaling #2002), anti α-tubulin (Abcam ab15246). Sec-
ondary antibodies used were; goat anti-mouse HRP
(DAKO P0447), goat anti-rabbit HRP (DAKO P0448),
anti-mouse Dy-Lite800 (Rockland 610-145-121), anti-
rabbit Dy-Lite680 (Rockland 611-144-122).
ATPase Viability Assay and Caspase Activity Assays
Cells were seeded at 5000/well into 96-well plates, (mini-
mum n = 5). After 24 h cells were treated with 10 ng/ml
recombinant human TRAIL (Calbiochem) or vehicle
control to final volume of 150 μl. Following 24 h treat-
ment, luminescent ATPase assay (Lonza) was carried out
according to manufacturer's instructions and 1 second
luminescence readings taken on a Berthold Tristar plate
reader. p-values were generated using Student's t-test.
For DEVDase activity assays, Casp3/7-glo reagent (Pro-
mega) was mixed 1:1 with RPMI and 50 μl applied to cells
after removal of culture media. Plates were incubated at
21°C for 30 minutes and luminescence read as before.
Flow Cytometry
Cells were seeded at a density of 1 × 105cells/well in 6-
well plates. Following treatment, DNA content was evalu-
ated by propidium iodide (PI, Sigma) staining of cells by
re-suspending them in 360 μL 0.1%FCS, 10 μg/mL PI,
0.25 mg/mL RNaseA in 1 xPBS. Samples were incubated
for 30 minutes prior to analysis on a FacsScalibur Flow
Cytometer (Becton Dickinson), in the FL-2 channel, to
determine percentage of cells with DNA content <2N. For
cell surface expression of receptor proteins, cells were
seeded as before, harvested, and rinsed twice in PBS/0.2%
BSA/0.2% Sodium Azide. Cells were resuspended in PBS/
BSA/sodium azide and incubated at 4°C for 60 minutes
with PE-conjugated antibodies to DR4, DR5, or isotype
control antibody. Staining intensity was measured on
flow cytometer in FL-2 channel.
Confocal Microscopy
Cells were seeded onto a glass coverslip inside a 6-well
plate and fixed in 2% paraformaldehyde. Coverslips were
incubated in PBS/0.1% Triton-X with 1:1000 dilutions of
anti-Caspase-8 and anti-COX-4 antibodies, for 1 h at
37°C with agitation, each followed by secondary antibod-
ies; goat anti-mouse AlexaFluor488 and goat anti rabbit
AlexaFluor594  (Invitrogen). Slides were mounted with
ProLong gold mountant (Invitrogen) and imaged on
Leica SP5 confocal microscope.
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